Clinton Hall, Sandra Maduforo, Celeste J Romano, Anna T Bukowinski, Gia R Gumbs, Ava Marie S Conlin
{"title":"妊娠期间接种Tdap或流感疫苗与临床绒毛膜羊膜炎的几率:一项巢式病例对照研究","authors":"Clinton Hall, Sandra Maduforo, Celeste J Romano, Anna T Bukowinski, Gia R Gumbs, Ava Marie S Conlin","doi":"10.1002/pds.70147","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the odds of clinical chorioamnionitis following tetanus, diphtheria, and acellular pertussis (Tdap) or influenza vaccine receipt in pregnancy.</p><p><strong>Methods: </strong>In this nested case-control study, a cohort of live deliveries at two United States military hospitals, 2013-2018, was initially screened for chorioamnionitis using diagnosis codes. A sample of deliveries was selected for chart review and validation. Study cases (clinical chorioamnionitis) were defined by the presence of fever and at least one additional clinical symptom during the delivery hospitalization; controls were defined by the absence of these criteria. Descriptive statistics compared characteristics of validated cases and controls, and multivariable logistic regression models estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) with receipt of Tdap or influenza vaccine during pregnancy; observations were weighted by the inverse probability of being sampled for validation.</p><p><strong>Results: </strong>Among 6931 deliveries, 1868 were sampled for validation and 1650 (n = 305 cases, n = 1345 controls) were included for analysis. At delivery, mean age was 25.0 years for cases and 25.9 years for controls; 88.4% of cases and 63.0% of controls were primipara. Tdap vaccine was recorded in 82.8% of cases and 82.0% of controls (aOR 0.94, 95% CI 0.72, 1.23) and influenza vaccine was recorded in 61.8% of cases and 63.0% of controls (aOR 0.97, 95% CI 0.78, 1.19). Analyses that considered timing and combinations of vaccine receipt yielded similar estimates.</p><p><strong>Conclusion: </strong>In this population, neither Tdap nor influenza vaccine receipt during pregnancy was associated with increased odds of clinical chorioamnionitis at delivery.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 4","pages":"e70147"},"PeriodicalIF":2.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Receipt of Tdap or Influenza Vaccine During Pregnancy and Odds of Clinical Chorioamnionitis: A Nested Case-Control Study.\",\"authors\":\"Clinton Hall, Sandra Maduforo, Celeste J Romano, Anna T Bukowinski, Gia R Gumbs, Ava Marie S Conlin\",\"doi\":\"10.1002/pds.70147\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the odds of clinical chorioamnionitis following tetanus, diphtheria, and acellular pertussis (Tdap) or influenza vaccine receipt in pregnancy.</p><p><strong>Methods: </strong>In this nested case-control study, a cohort of live deliveries at two United States military hospitals, 2013-2018, was initially screened for chorioamnionitis using diagnosis codes. A sample of deliveries was selected for chart review and validation. Study cases (clinical chorioamnionitis) were defined by the presence of fever and at least one additional clinical symptom during the delivery hospitalization; controls were defined by the absence of these criteria. Descriptive statistics compared characteristics of validated cases and controls, and multivariable logistic regression models estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) with receipt of Tdap or influenza vaccine during pregnancy; observations were weighted by the inverse probability of being sampled for validation.</p><p><strong>Results: </strong>Among 6931 deliveries, 1868 were sampled for validation and 1650 (n = 305 cases, n = 1345 controls) were included for analysis. At delivery, mean age was 25.0 years for cases and 25.9 years for controls; 88.4% of cases and 63.0% of controls were primipara. Tdap vaccine was recorded in 82.8% of cases and 82.0% of controls (aOR 0.94, 95% CI 0.72, 1.23) and influenza vaccine was recorded in 61.8% of cases and 63.0% of controls (aOR 0.97, 95% CI 0.78, 1.19). Analyses that considered timing and combinations of vaccine receipt yielded similar estimates.</p><p><strong>Conclusion: </strong>In this population, neither Tdap nor influenza vaccine receipt during pregnancy was associated with increased odds of clinical chorioamnionitis at delivery.</p>\",\"PeriodicalId\":19782,\"journal\":{\"name\":\"Pharmacoepidemiology and Drug Safety\",\"volume\":\"34 4\",\"pages\":\"e70147\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacoepidemiology and Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pds.70147\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70147","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
目的:评价妊娠期接种破伤风、白喉、无细胞百日咳(Tdap)或流感疫苗后发生绒毛膜羊膜炎的几率。方法:在这项巢式病例对照研究中,使用诊断代码对2013-2018年两家美国军事医院的活产队列进行绒毛膜羊膜炎筛查。选择一个交付样本进行图表审查和验证。研究病例(临床绒毛膜羊膜炎)的定义是在分娩住院期间出现发烧和至少一种额外的临床症状;对照的定义是没有这些标准。描述性统计比较了验证病例和对照组的特征,多变量logistic回归模型估计了妊娠期间接种百白破或流感疫苗的校正优势比(aORs)和95%置信区间(ci);观察值被抽样验证的逆概率加权。结果:6931例分娩中,1868例进行验证,1650例(n = 305例,对照n = 1345例)进行分析。分娩时,病例的平均年龄为25.0岁,对照组为25.9岁;初产妇占88.4%,对照组占63.0%。82.8%的病例和82.0%的对照组接种了百白破疫苗(aOR 0.94, 95% CI 0.72, 1.23), 61.8%的病例和63.0%的对照组接种了流感疫苗(aOR 0.97, 95% CI 0.78, 1.19)。考虑疫苗接种时间和组合的分析得出了类似的估计。结论:在这一人群中,妊娠期间接种Tdap和流感疫苗均与分娩时临床绒毛膜羊膜炎的几率增加无关。
Receipt of Tdap or Influenza Vaccine During Pregnancy and Odds of Clinical Chorioamnionitis: A Nested Case-Control Study.
Objective: To evaluate the odds of clinical chorioamnionitis following tetanus, diphtheria, and acellular pertussis (Tdap) or influenza vaccine receipt in pregnancy.
Methods: In this nested case-control study, a cohort of live deliveries at two United States military hospitals, 2013-2018, was initially screened for chorioamnionitis using diagnosis codes. A sample of deliveries was selected for chart review and validation. Study cases (clinical chorioamnionitis) were defined by the presence of fever and at least one additional clinical symptom during the delivery hospitalization; controls were defined by the absence of these criteria. Descriptive statistics compared characteristics of validated cases and controls, and multivariable logistic regression models estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) with receipt of Tdap or influenza vaccine during pregnancy; observations were weighted by the inverse probability of being sampled for validation.
Results: Among 6931 deliveries, 1868 were sampled for validation and 1650 (n = 305 cases, n = 1345 controls) were included for analysis. At delivery, mean age was 25.0 years for cases and 25.9 years for controls; 88.4% of cases and 63.0% of controls were primipara. Tdap vaccine was recorded in 82.8% of cases and 82.0% of controls (aOR 0.94, 95% CI 0.72, 1.23) and influenza vaccine was recorded in 61.8% of cases and 63.0% of controls (aOR 0.97, 95% CI 0.78, 1.19). Analyses that considered timing and combinations of vaccine receipt yielded similar estimates.
Conclusion: In this population, neither Tdap nor influenza vaccine receipt during pregnancy was associated with increased odds of clinical chorioamnionitis at delivery.
期刊介绍:
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.
Particular areas of interest include:
design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
assessments of harm versus benefit in drug therapy;
patterns of drug utilization;
relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.